Effectiveness of a Third TNF-α-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in RA
M. Blom, W. Kiewit, A.R.T. Donders, et al. 2355

Free online via JRheum Full Release option


Resistin Levels in Lupus and Associations with Disease-specific Measures, Insulin Resistance, and Coronary Calcification J.F. Baker, M. Morales, M. Qatanani, et al. 2369

Association Analysis of Polymorphisms in Lumican Gene and SLE in a Taiwan Chinese Han Population P-C. Chang, Y. Chen, M-T. Lai, et al. 2376

Undertreatment of Disease Activity in SLE Patients with Endstage Renal Failure Is Associated with Increased All-cause Mortality A. Broder, S. Khattri, R. Patel, C. Putteman. 2382


SLEDAI 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials Y. Qiao, H.D. Gladman, D. Ibañez, Z. Yan, A.L. Young, H. Hua, Y. Xu. 2395

High Risk of Ischemic Heart Disease in Patients with Lupus Nephritis M. Faurschou, L. Mellemkjaer, H. Starklint, A-L. Kamper, U. Tarp, A. Voss, S. Jacobsen. 2400


Tricuspid Annular Plane Systolic Excursion Is a Robust Outcome Measure in SSc-associated Pulmonary Arterial Hypertension S.C. Mathai, C.T. Sibley, P.R. Forfia, et al. 2410

Analysis of the Validation Status of Quality of Life and Functional Disability Measures in PAH Related to SSc: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS) O. Kowal-Bielecka, J. Avouac, D. Pittrow, et al, for the EPOSS. 2419

Multiple Oral Candida Infections in Patients with Sjögren’s Syndrome — Prevalence and Clinical and Drug Susceptibility Profiles Z. Yan, A.L. Young, H. Hua, Y. Xu. 2428
Images in Rheumatology


Correspondence

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis N. Jourde-Chiche, E. Daugas ............................ 2490
Reply K. Laskari, A.G. Tzioufas, H.M. Moutsopoulos .... 2490

Reply I.R. Varaprasad, S. Agrawal .................. 2491

Significantly Decreased Serum 25-OHD Levels in a Large German Systemic Sclerosis Cohort T. Gambichler, I. Chrobok, S. Héxtermann, A. Kreuter . 2492
Reply R. Rios Fernández, J-L. Callejas Rubio, C. Fernández Roldán, N. Ortego Centeno ............... 2493

Letters


GCA as a Cause of Acute Myocarditis in the Elderly G. Pugnet, A. Pathak, N. Dumonteil, L. Sailler ........... 2497

Correction

Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis M. Baron, M. Hudson, R. Steele, E. Lo, and the Canadian Scleroderma Research Group ............ 2498

Meetings in Rheumatology ........................................... xi

Pediatric Rheumatology

Levels of Serum MMP-3 Correlate with Disease Activity in the Enthesitis-related Arthritis Category of JIA V. Viswanath, A. Myles, R. Dayal, A. Aggarwal ............ 2482

Idiopathic Inflammatory Myopathy Associated with Malignancy: A Retrospective Cohort of 151 Korean Patients with DM and PM M.W. So, B.S. Koo, Y-G. Kim, C-K. Lee, B. Yoo ......... 2432


Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care D. Podubnyj, J. Vahldiek, I. Spiller, B. Buss, J. Listing, M. Rudwaleit, J. Sieper ............ 2452

Minimally Important Difference of HAQ in PsA: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction P.J. Mease, J.M. Woolley, B. Bitman, B.C. Wang, D.R. Globe, A. Singh ..................... 2461

Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe PsA: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial G.N. Karanikolas, E-M. Koukli, A. Katsalira, et al ............. 2466

MRI Bone Edema Is Not a Major Feature of Gout Unless There Is Concomitant Osteomyelitis: 10-year Findings from a High-prevalence Population Y.J. Poh, N. Dalbeth, A. Doyle, F.M. McQueen .......... 2475

Images in Rheumatology


Correspondence

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis N. Jourde-Chiche, E. Daugas ............................ 2490
Reply K. Laskari, A.G. Tzioufas, H.M. Moutsopoulos .... 2490

Reply I.R. Varaprasad, S. Agrawal .................. 2491

Significantly Decreased Serum 25-OHD Levels in a Large German Systemic Sclerosis Cohort T. Gambichler, I. Chrobok, S. Héxtermann, A. Kreuter . 2492
Reply R. Rios Fernández, J-L. Callejas Rubio, C. Fernández Roldán, N. Ortego Centeno ............... 2493

Letters


GCA as a Cause of Acute Myocarditis in the Elderly G. Pugnet, A. Pathak, N. Dumonteil, L. Sailler ........... 2497

Correction

Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis M. Baron, M. Hudson, R. Steele, E. Lo, and the Canadian Scleroderma Research Group ............ 2498

Meetings in Rheumatology ........................................... xi